Just in
HealthVerified by 3 independent sources

Pancreatic cancer pill shrinks tumours in 60.7% of trial patients

Tumours shrank or disappeared in 60.7 per cent of 61 patients with advanced pancreatic cancer who took daraxonrasib with chemotherapy. Researchers presented the early-trial results in Barcelona and say larger studies are needed.

Pancreatic cancer pill shrinks tumours in 60.7% of trial patients
Photo: Gam-Ol / Pixabay

For information only, not medical advice. Talk to a doctor about your own health.

KEY POINTS
  • Daraxonrasib plus chemotherapy produced a confirmed response in 60.7% of 61 patients
  • Five patients (8.2%) had no detectable tumours on scans, which does not mean a cure
  • Researchers say the study was small and had no randomised control group
  • A larger phase III trial, RASolute 303, is under way
60.7%Patients with confirmed response
61Patients in trial
12.8 monthsMedian progression-free survival
8.2%Complete response

A daily pill combined with chemotherapy shrank tumours in about six in 10 patients with advanced pancreatic cancer in an early trial, according to results presented on Friday at the EORTC-NCI-AACR Symposium in Barcelona.

The trial tested the drug daraxonrasib in 61 patients whose cancer had spread to other parts of the body. None had previously received treatment for metastatic disease. Patients took a daily 200mg tablet alongside the chemotherapy drugs gemcitabine and nab-paclitaxel.

Tumours shrank or disappeared in 60.7 per cent of patients. Five patients, or 8.2 per cent, showed no detectable tumours on scans. Dr Wungki Park of Memorial Sloan Kettering Cancer Center, who led the research, said: "In about one in 12 patients, it [the cancer] completely disappeared". He also called the result "a massive, massive breakthrough". Researchers stressed that no detectable tumour does not mean a patient has been cured.

The disease was kept from progressing in 90.2 per cent of patients, according to EORTC. After a median follow-up of 18.3 months, the median time before the cancer worsened or patients died was 12.8 months. Of the patients, 76.6 per cent were still alive 12 months after starting treatment. EORTC said patients with metastatic pancreatic cancer on conventional chemotherapy typically survive eight to 11 months.

Researchers cautioned that the study was small and lacked a randomised comparison with chemotherapy alone, so comparisons with earlier chemotherapy studies cannot show whether the combination extends lives. Professor Shivan Sivakumar called the results "very encouraging" but added: "We do not yet know whether these promising results will translate into longer overall survival".

Common side effects included rash, diarrhoea, fatigue and reduced blood cell counts. About 5 per cent of patients stopped treatment because of side effects attributed to daraxonrasib.

Daraxonrasib, developed by US company Revolution Medicines, blocks active RAS proteins, which are mutated in more than 90 per cent of pancreatic cancers. The US FDA approved it, marketed as Rasonque, on 26 August for certain adults with metastatic pancreatic cancer who had at least one earlier treatment or cannot receive multidrug therapy. In a separate trial of 500 patients, the FDA said median overall survival was 13.2 months with the drug against 6.7 months with standard chemotherapy.

The use of the combination as first treatment still needs further validation. The phase III trial RASolute 303 is comparing daraxonrasib alone, and with chemotherapy, against chemotherapy alone in patients not previously treated.

Why it matters for Pakistan

Pancreatic cancer patients and their families in Pakistan may follow these results closely, as the pakistanAngle notes that advances in treatment matter to them. The pill is not yet available in Pakistan. The researchers themselves say the trial was small and that it is not known whether the combination improves survival.

Report an error

Pancreatic cancerCancer treatment

Related news

Latest